CROMWELL, Conn. & MADISON, Wis.--(BUSINESS WIRE)--Jun 6, 2018--Biological Industries USA ( BI-USA ), a division of Biological Industries Beit Haemek Israel (BI), and Primorigen Biosciences, Inc. announce a strategic partnership for non-exclusive worldwide distribution of Primorigen’s proprietary Vitronectin XF ™ protein matrix for stem cell culture.

“Primorigen and Vitronectin XF™ are an excellent fit with BI-USA’s strategic goal of providing defined and reliable solutions to further advance stem cell research, cell therapy development, and drug discovery,” commented Daniel Haus, PhD, Scientific Affairs Manager at BI-USA.

Vitronectin XF™ is a widely used defined recombinant human protein for human pluripotent stem cell (hPSC) attachment, growth, and differentiation. The new agreement adds a key asset to the extensive BI-USA portfolio of stem cell culture solutions and will be distributed under the Primorigen brand. BI-USA has performed extensive evaluation of Vitronectin XF™ in combination with BI’s NutriStem® hPSC Medium, resulting in consistent long-term culture of pluripotent cells in a chemically defined, xeno-free environment.

“BI-USA’s products and dedication to the stem cell and regenerative medicine fields nicely complement Primorigen's, and will enable the scientific community to further leverage the many benefits of Vitronectin XF™,” said Chuck Oehler, CEO of Primorigen.

About Biological Industries USA (BI-USA)

Biological Industries USA ( www.bioindusa.com ) is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share expertise and a history of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine.

To receive ongoing BI communications, please join our email list or connect with the company at  www.bioindusa.com  or via  LinkedInTwitter, and  Facebook.

About Biological Industries (BI)

Biological Industries ( www.bioind.com ) is one of the world’s leading and trusted suppliers to the life sciences industry, with over 35 years’ experience in cell culture media development and GMP manufacturing. BI’s products range from classical cell culture media, to supplements and reagents for stem cell research and cell therapy applications, to serum and serum-free media products. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.

About Primorigen Biosciences, Inc.

Primorigen Biosciences, Inc. ( www.primorigen.com ) provides innovative solutions for stem cell maintenance, proliferation, and large-scale production. Products include defined, xenobiotic-free matrices for easier, more reliable and less expensive stem cell culture, advanced coated microcarriers for consistent large-scale cell production in suspension, high quality monoclonal antibodies validated for stem cell characterization--including flow cytometry, human cytokines and growth factors, recombinant developmental protein markers, and others. Primorigen’s technologies have been validated by growing sales, strategic partnerships with leading companies and academic laboratories worldwide, and multiple highly competitive research and development funding awards from the U.S. National Institutes of Health.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606006187/en/

CONTACT: BI-USA:

Daniel Haus, PhD, Scientific Affairs

860-316-2702

dhaus@bioindusa.com

or

Primorigen Biosciences:

Chuck Oehler, CEO

608-441-8332

Info@primorigen.com

or

Media:

Gotham Communications, LLC

Bill Douglass, 646-504-0890

bill@gothamcomm.com

KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT WISCONSIN

INDUSTRY KEYWORD: STEM CELLS TECHNOLOGY OTHER TECHNOLOGY HEALTH BIOTECHNOLOGY MANUFACTURING CHEMICALS/PLASTICS NATURAL RESOURCES AGRICULTURE RESEARCH SCIENCE

SOURCE: Biological Industries USA

Copyright Business Wire 2018.

PUB: 06/06/2018 02:00 PM/DISC: 06/06/2018 05:46 PM

http://www.businesswire.com/news/home/20180606006187/en